Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.50 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.47 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.47 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.47 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.47 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GUSB | P08236 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.42 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15805101 | 1.00 | SLC18A2 (0.50) | SLC18A2TRPM5ALDH1A1SMN1; SMN2HTR2A | |
| SCHEMBL15797739 | 1.00 | SLC18A2 (0.50) | SLC18A2TRPM5ALDH1A1SMN1; SMN2HTR2A | |
| SCHEMBL15805066 | 1.00 | SLC18A2 (0.50) | SLC18A2TRPM5ALDH1A1SMN1; SMN2HTR2A | |
| SCHEMBL1799795 | 0.84 | KDM4E (0.47) | SLC18A2ALDH1A1HTR2CMAPTPKM | |
| SCHEMBL1798877 | 0.84 | KDM4E (0.47) | SLC18A2ALDH1A1HTR2CMAPTPKM | |
| SCHEMBL2934392 | 0.84 | KDM4E (0.47) | SLC18A2ALDH1A1HTR2CMAPTPKM | |
| SCHEMBL1800153 | 0.84 | KDM4E (0.47) | SLC18A2ALDH1A1HTR2CMAPTPKM | |
| SCHEMBL6082093 | 0.84 | KDM4E (0.47) | SLC18A2ALDH1A1HTR2CMAPTPKM | |
| SCHEMBL14549989 | 0.83 | ALDH1A1 (0.47) | ALDH1A1HTR2AHTR2CHTR2BMAPT | |
| SCHEMBL4140870 | 0.83 | ALDH1A1 (0.47) | ALDH1A1HTR2AHTR2CHTR2BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2931708-B1 | CYCLOPROPYLBORONIC COMPOUNDS, METHOD FOR PREPARING SAME AND USE THEREOF | DIVERCHIM (FR) | 2017-05-10 | — | — | EP | disclosed |
| EP-2931708-B1 | CYCLOPROPYLBORONIC COMPOUNDS, METHOD FOR PREPARING SAME AND USE THEREOF | DIVERCHIM (FR) | 2017-05-10 | — | — | EP | disclosed |
| US-9527798-B2 | Cyclopropylboronic compounds, preparation process thereof and use thereof | DIVERCHIM (FR) | 2016-12-27 | — | — | US | disclosed |
| US-20150329566-A1 | CYCLOPROPYLBORONIC COMPOUNDS, METHOD FOR PREPARING SAME AND USE THEREOF | DIVERCHIM (FR) | 2015-11-19 | — | — | US | disclosed |
| EP-2931708-A2 | CYCLOPROPYLBORONIC COMPOUNDS, METHOD FOR PREPARING SAME AND USE THEREOF | Diverchim (FR) | 2015-10-21 | — | — | EP | disclosed |
| EP-2268641-B1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS PVT LTD (IN) | 2014-09-03 | — | — | EP | disclosed |
| EP-2268641-B1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS PVT LTD (IN) | 2014-09-03 | — | — | EP | disclosed |
| WO-2014091167-A2 | CYCLOPROPYLBORONIC COMPOUNDS, METHOD FOR PREPARING SAME AND USE THEREOF | DIVERCHIM (FR) | 2014-06-19 | — | — | WO | disclosed |
| US-8252797-B2 | Heterocyclic compounds as adenosine receptor antagonist | ADVINUS THERAPEUTICS PVT. LTD. (IN) | 2012-08-28 | — | — | US | disclosed |
| US-8252797-B2 | Heterocyclic compounds as adenosine receptor antagonist | ADVINUS THERAPEUTICS PVT. LTD. (IN) | 2012-08-28 | — | — | US | disclosed |
| EP-2268641-A2 | HETEROCYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | Advinus Therapeutics Pvt. Ltd. (IN) | 2011-01-05 | — | — | EP | disclosed |
| US-20090298744-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS PVT. LTD. (IN) | 2009-12-03 | — | — | US | disclosed |
| US-20090298744-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS PVT. LTD. (IN) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329566-A1 | CYCLOPROPYLBORONIC COMPOUNDS, METHOD FOR PREPARING SAME AND USE THEREOF | HMBS, MMAB, FDPS | SLC18A2 2368/4885TRPM5 4507/4885ALDH1A1 1615/4885 |
| US-20090298744-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADORA2A, ADORA3, ADORA1 | SLC18A2 264/4885TRPM5 298/4885ALDH1A1 551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.